$3.23
0.62% today
Nasdaq, Feb 28, 04:51 pm CET
ISIN
US75943R1023
Symbol
RLAY
Sector
Industry

Relay Therapeutics Inc Stock price

$3.25
-1.47 31.14% 1M
-3.89 54.48% 6M
-0.87 21.12% YTD
-7.04 68.42% 1Y
-20.86 86.52% 3Y
-31.80 90.73% 5Y
-31.80 90.73% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.50 13.33%
ISIN
US75943R1023
Symbol
RLAY
Sector
Industry

Key metrics

Market capitalization $543.99m
Enterprise Value $-188.83m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.75
EV/Sales (TTM) EV/Sales -18.86
P/S ratio (TTM) P/S ratio 54.34
P/B ratio (TTM) P/B ratio 0.70
Revenue growth (TTM) Revenue growth -60.83%
Revenue (TTM) Revenue $10.01m
EBIT (operating result TTM) EBIT $-385.67m
Free Cash Flow (TTM) Free Cash Flow $-251.13m
Cash position $781.32m
EPS (TTM) EPS $-2.40
P/E forward negative
P/S forward 154.71
EV/Sales forward negative
Short interest 11.35%
Show more

Is Relay Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Relay Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Relay Therapeutics Inc forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a Relay Therapeutics Inc forecast:

Buy
92%
Hold
8%

Financial data from Relay Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
10 10
61% 61%
100%
- Direct Costs 5.46 5.46
4% 4%
55%
4.54 4.54
78% 78%
45%
- Selling and Administrative Expenses 66 66
2% 2%
656%
- Research and Development Expense 319 319
3% 3%
3,188%
-380 -380
2% 2%
-3,798%
- Depreciation and Amortization 5.46 5.46
4% 4%
55%
EBIT (Operating Income) EBIT -386 -386
2% 2%
-3,853%
Net Profit -338 -338
1% 1%
-3,374%

In millions USD.

Don't miss a Thing! We will send you all news about Relay Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Relay Therapeutics Inc Stock News

Neutral
GlobeNewsWire
2 days ago
Initiation of Phase 3 ReDiscover-2 trial of RLY-2608 + fulvestrant anticipated in the middle of 2025 in PI3Kα-mutated, CDK4/6 pre-treated, HR+/HER2- metastatic breast cancer
Neutral
GlobeNewsWire
4 days ago
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in two upcoming fireside chats: TD Cowen's 45th Annual Health Care Conference on Wednesday, March 5,...
Neutral
GlobeNewsWire
9 days ago
CAMBRIDGE, Mass., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report fourth quarter and full year 2024 financial results and corporate highlights after the U.S. financial markets close on Wednesday, Februar...
More Relay Therapeutics Inc News

Company Profile

Relay Therapeutics, Inc. is a clinical-stage precision medicines company. It focuses on using innovative experimental and computational approaches on protein motion for making medicines against intractable precision medicine targets. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Sanjiv Patel
Employees 261
Founded 2015
Website www.relaytx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today